• LAST PRICE
    3.0056
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.1800/ 2
  • Ask / Lots
    4.6200/ 2
  • Open / Previous Close
    --- / 3.0056
  • Day Range
    ---
  • 52 Week Range
    Low 1.0775
    High 4.4000
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3
TimeVolumeAKTX
09:41 ET2502.9874
11:22 ET1682.98
11:44 ET4002.855
12:07 ET2002.9799
12:20 ET1002.901822
12:27 ET2002.9
12:34 ET17202.89
12:43 ET2003.0056
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAKTX
Akari Therapeutics PLC
36.5M
-1.0x
---
United StatesSRZN
Surrozen Inc
36.2M
-0.5x
---
United StatesTARA
Protara Therapeutics Inc
36.9M
-0.6x
---
United StatesTPST
Tempest Therapeutics Inc
35.8M
-0.9x
---
United StatesNXTC
NextCure Inc
37.8M
-0.6x
---
United StatesACXP
Acurx Pharmaceuticals Inc
34.9M
-1.9x
---
As of 2024-10-07

Company Information

Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.

Contact Information

Headquarters
22 BOSTON WHARF ROAD, FL 7BOSTON, MA, United States 02210
Phone
646-350-0702
Fax
646-843-9352

Executives

Independent Chairman of the Board
Raymond Prudo-chlebosz
Interim President, Interim Chief Executive Officer, Director
Samir Patel
Interim Chief Financial Officer
Wendy Dicicco
Independent Director
Robert Bazemore
Independent Director
Michael Grissinger

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$36.5M
Revenue (TTM)
$0.00
Shares Outstanding
607.2K
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.93
EPS
$-2.98
Book Value
$-0.03
P/E Ratio
-1.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.